Mylovenge: Phase II

Long-term follow-up of Phase II trials of Mylovenge showed that the product gave tumor regression or disease stabilization in 16 of 42 multiple myeloma patients, with 6 of those patients showing decreases in serum M protein. A total of 10 of those patients had stable disease for >6 months, with 4 patients stable for >18 months. In a separate trial of 17 myeloma patients with residual disease 100 days post-stem cell transplant, 5 had clinical responses, including 3 complete responses, 1 near complete response and 1 partial response. A total of 8 patients developed disease progression following completion of treatment, 5 of whom progressed ?12 months after enrollment. ...